{"id":"placebo-glimepiride","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1481","moleculeType":"Small molecule","molecularWeight":"490.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this formulation contains no glimepiride or other active drug substance. It is used as a control in clinical trials to assess the placebo effect and distinguish true drug efficacy from patient expectation or natural disease progression. Any observed clinical benefit would be attributable to placebo response rather than direct pharmacological action.","oneSentence":"Placebo glimepiride is an inert formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:04.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00974090","phase":"PHASE3","title":"Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":194},{"nctId":"NCT07288749","phase":"PHASE3","title":"Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF)","enrollment":1484},{"nctId":"NCT01242215","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-09-17","conditions":"Type 2 Diabetes Mellitus","enrollment":243},{"nctId":"NCT01951339","phase":"NA","title":"Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-10","conditions":"Type 2 Diabetes, Cardiovascular Disease","enrollment":36},{"nctId":"NCT03907423","phase":"NA","title":"Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin","status":"COMPLETED","sponsor":"Rehab Werida","startDate":"2019-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT05162690","phase":"PHASE2, PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":40},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":954},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":3118},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT01243424","phase":"PHASE3","title":"CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11-11","conditions":"Diabetes Mellitus, Type 2","enrollment":6103},{"nctId":"NCT01644500","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":737},{"nctId":"NCT03081676","phase":"NA","title":"The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2017-03-08","conditions":"Maturity-Onset Diabetes of the Young, Type 3","enrollment":20},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02728453","phase":"PHASE4","title":"SGLT2 Inhibition and Left Ventricular Mass","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2016-04-27","conditions":"Diabetes Mellitus Type 2","enrollment":7},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT02985242","phase":"PHASE4","title":"Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-06-12","conditions":"Diabetes Mellitus, Type II","enrollment":6},{"nctId":"NCT02226003","phase":"PHASE3","title":"Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":291},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01704261","phase":"PHASE3","title":"Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-18","conditions":"Type 2 Diabetes Mellitus","enrollment":307},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT01863667","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-07-08","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01614769","phase":"PHASE1","title":"Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT01189890","phase":"PHASE3","title":"Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08-16","conditions":"Type 2 Diabetes Mellitus","enrollment":480},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00614120","phase":"PHASE3","title":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT00620282","phase":"PHASE3","title":"The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":49},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT00294723","phase":"PHASE3","title":"To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":746},{"nctId":"NCT01233622","phase":"PHASE3","title":"Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT01934816","phase":"NA","title":"Incretin and KATP Channels","status":"TERMINATED","sponsor":"Katarina Kos","startDate":"2013-06","conditions":"Healthy Subjects","enrollment":2},{"nctId":"NCT01517373","phase":"PHASE2","title":"Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2","enrollment":304},{"nctId":"NCT01511692","phase":"PHASE1","title":"Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":43},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT01509755","phase":"PHASE2","title":"Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":196},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01167881","phase":"PHASE3","title":"Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1549},{"nctId":"NCT01829477","phase":"PHASE3","title":"Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-04","conditions":"Diabetes Mellitus, Type 2","enrollment":33},{"nctId":"NCT01990469","phase":"PHASE3","title":"Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2014-01","conditions":"T2DM","enrollment":219},{"nctId":"NCT01007097","phase":"PHASE2","title":"Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-12","conditions":"Diabetes Mellitus, Type 2","enrollment":426},{"nctId":"NCT01769378","phase":"PHASE3","title":"Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT01703286","phase":"PHASE1","title":"Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-10","conditions":"Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT01494987","phase":"PHASE3","title":"Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":431},{"nctId":"NCT00309608","phase":"PHASE2","title":"Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Diabetes Mellitus, Type 2","enrollment":333},{"nctId":"NCT01087502","phase":"PHASE3","title":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":241},{"nctId":"NCT00740051","phase":"PHASE3","title":"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-08","conditions":"Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT01357252","phase":"PHASE3","title":"Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04","conditions":"Type 2 Diabetes Mellitus","enrollment":279},{"nctId":"NCT02089126","phase":"PHASE3","title":"Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"LG Life Sciences","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus","enrollment":230},{"nctId":"NCT00622284","phase":"PHASE3","title":"Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1560},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597},{"nctId":"NCT01699737","phase":"PHASE2","title":"Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":325},{"nctId":"NCT01585792","phase":"PHASE3","title":"Double Blind Comparative Study of TAK-875","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-05","conditions":"Diabetic Patients","enrollment":80},{"nctId":"NCT01496443","phase":"PHASE1","title":"TAK-875 Glimepiride Drug-Interaction Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"Pharmacokinetics","enrollment":28},{"nctId":"NCT00363519","phase":"PHASE3","title":"Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus","enrollment":195},{"nctId":"NCT00099944","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":515},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT01318083","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT00947557","phase":"PHASE3","title":"Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2009-07","conditions":"Diabetes Mellitus, Type II","enrollment":677},{"nctId":"NCT01068860","phase":"PHASE2","title":"To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":246},{"nctId":"NCT00924573","phase":"PHASE3","title":"Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":189},{"nctId":"NCT01133431","phase":"PHASE1","title":"The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-05","conditions":"Healthy Male Volunteer","enrollment":24},{"nctId":"NCT00770653","phase":"PHASE3","title":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":"Diabetes Mellitus, Dyslipidemias","enrollment":305},{"nctId":"NCT00770952","phase":"PHASE3","title":"Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-12","conditions":"Diabetes Mellitus","enrollment":91},{"nctId":"NCT00044447","phase":"PHASE3","title":"Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo glimepiride","genericName":"placebo glimepiride","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}